- Home
- LXRX vs HQL Comparison
LXRX vs HQL Comparison
Compare LXRX & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXRX | HQL |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.2M | 510.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | HQL |
|---|---|---|
| Price | $1.82 | $17.28 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.23 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 120.9K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $70,864,000.00 | N/A |
| Revenue This Year | $56.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.08 |
| Revenue Growth | ★ 1255.21 | N/A |
| 52 Week Low | $0.28 | $11.34 |
| 52 Week High | $1.66 | $14.37 |
Technical Indicators
Market Signals| Indicator | LXRX | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 79.59 | 58.81 |
| Support Level | $1.25 | $16.35 |
| Resistance Level | $1.41 | $17.01 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 99.24 | 90.67 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.